Why Natera Stock Is Down 14.6% And What's Next

Simply Wall St.11-08 06:18

Natera reported Q3 2026 revenue of US$793.98 million and a net loss of US$59.91 million, raised full year revenue guidance above US$3b, and at the same time announced that long time executive Solomon ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2681845191?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944","is_english":true,"pubTime":"2026-11-08 06:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2681845191","market":"hk","top_or_hot":-1,"title":"Why Natera Stock Is Down 14.6% And What's Next","media":"Simply Wall St.","content":"<div>\n<p>Natera reported Q3 2026 revenue of US$793.98 million and a net loss of US$59.91 million, raised full year revenue guidance above US$3b, and at the same time announced that long time executive Solomon ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/why-natera-stock-is-down-146-and-whats-next\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Natera Stock Is Down 14.6% And What's Next</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Natera Stock Is Down 14.6% And What's Next\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-11-08 06:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/why-natera-stock-is-down-146-and-whats-next><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Natera reported Q3 2026 revenue of US$793.98 million and a net loss of US$59.91 million, raised full year revenue guidance above US$3b, and at the same time announced that long time executive Solomon ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/why-natera-stock-is-down-146-and-whats-next\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065169927.USD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/why-natera-stock-is-down-146-and-whats-next","article_id":"2681845191","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=240/https://images.simplywall.st/asset/industry/6111000-choice2-card/1788928698944"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntra/natera/news/why-natera-stock-is-down-146-and-whats-next","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2681845191","pubTimestamp":1794089890,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"BBailey PembertonNovember 7, 2026","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","GNOM":"Global X Genomics & Biotechnology ETF","LU0012050646.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" (USD) INC AV","BK4139":"生物科技","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","LU0106261612.USD":"SCHRODER ISF US SMALLER COMPANIES IMPACT \"A\" ACC","LU1988902786.USD":"FULLERTON LUX FUNDS GLOBAL ABSOLUTE ALPHA \"I\" (USD) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU0345770308.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) ACC","LU0345770993.USD":"NINETY ONE GSF GLOBAL STRATEGIC EQUITY \"A\" (USD) INC","NTRA":"Natera, Inc.","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","HELX":"Franklin Genomic Advancements ETF","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)"},"translate_title":"为什么 Natera 股价下跌 14.6% 以及下一步会发生什么","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTRA":1.5,"GNOM":0.6,"HELX":0.6},"content_text":"Natera reported Q3 2026 revenue of US$793.98 million and a net loss of US$59.91 million, raised full year revenue guidance above US$3b, and at the same time announced that long time executive Solomon Moshkevich would replace Steve Chapman as CEO and join the board. The past week also brought fresh clinical data for Signatera across multiple cancers, with studies highlighting how molecular residual disease testing may inform treatment decisions and surveillance, underscoring how Natera’s oncology franchise is shaping its operating profile even as profitability remains under pressure. We will now look at how Natera's investment narrative is affected by the surprise CEO handover alongside upgraded revenue guidance.  Scan how the Natera story fits into a broader oncology and diagnostics trend by comparing it with 35 healthcare AI stocks that are already on investors’ radar. AdvertisementNatera Investment Narrative Recap For Natera, the core belief is that molecular diagnostics, especially Signatera and the broader oncology and organ health portfolio, can keep driving higher test volumes and improved economics over time. Q3 2026 revenue of US$793.98 million and raised full year guidance above US$3b support that operating momentum, even though the company still reported a net loss of US$59.91 million. In the near term, investors are likely to focus on two things. First, whether oncology growth and reimbursement trends remain strong enough to offset heavy R&D and SG&A spend and gradually shrink losses. Second, whether the abrupt CEO transition creates any disruption in execution, especially as management leans into higher volumes, expanding trials and rising operating costs. The CEO switch to Solomon Moshkevich on November 5, 2026 is the announcement that ties most directly to the current setup. He has run major parts of Natera’s operations since 2011, including clinical diagnostics and oncology, where Signatera has become central to the business. That tenure and product familiarity may help reduce uncertainty around product priorities and commercial focus. From a catalyst point of view, the key question is whether this leadership change sustains or improves execution on oncology test uptake, payer coverage and cost discipline while Natera is still loss making. Any stumble on trial outcomes, reimbursement decisions or spending control would feed directly into the biggest existing risks, which are ongoing net losses, high investment needs and an already full valuation on P/S metrics. Natera's narrative projects US$4.8b revenue and US$405.4 million earnings by 2029. This implies 21.1% yearly revenue growth and an earnings improvement of about US$598 million from current earnings, which are a US$192.3 million loss. Uncover why Natera's fair value indicates a 34% potential upside to its current price that could narrow quickly. NasdaqGS:NTRA 1-Year Stock Price Chart Exploring Other Perspectives Some of the most pessimistic analysts worry that Natera’s heavy early detection and lab spending could struggle to earn its keep. Before this CEO switch and guidance hike, that group was modeling roughly US$4.5b revenue and US$718.9 million earnings by 2029, compared with US$4.8b and US$405.4 million in the baseline. This contrast shows how sharply opinions can diverge. Use this earnings release and leadership change as a fresh lens to compare those narratives for yourself. Explore 4 other Natera fair value estimates, including one that suggests up to 10% downside from the current price. Decide For Yourself Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider forming your own view based on research and analysis.  A great starting point for your Natera research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. See our latest analysis for Natera. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easier to evaluate Natera's overall financial health at a glance.  Looking For More Investment Ideas Beyond Natera? If this Natera update has sharpened your thinking about risk, growth and valuation, use that same lens to scan a broader field of potential opportunities with the Simply Wall St Screener.  Prefer quality at a discount and want businesses with stronger fundamentals than their price suggests, start with 39 high quality undervalued stocks to see which candidates fit that brief. If resilience matters most and you care about balance sheets that can absorb shocks, focus on the list of solid balance sheet and fundamentals (24 results) to narrow the field quickly. Looking for companies that the market has not crowded yet but still have solid underlying metrics, use the 19 high quality undiscovered gems to surface ideas that might not be on every watchlist.  This article is general in nature and was produced with the assistance of AI automation,\n        based on data and analysis from Simply Wall St. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Natera might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2681845191","isCrawlerRequest":true}